Strong six-month sales help Boehringer build on stellar 2017

Family-owned German drugmaker Boehringer Ingelheim has issued a statement related to its financial performance in first-half 2018, indicating the firm achieved “modest growth,” with net revenues of 8.6 billion euros ($10 billion).

Highlighting significant investments, particularly in the German and French markets, the firm claims that of some 80 development projects, 65% have “the potential for a therapeutic breakthrough or to be the first active ingredient in a new class.”

While the firm grew in all of its businesses, growth was down from last year, partly due to increased generic competition in the Japanese cardiovascular market.